Toxicities Hinder Potential Efficacy of Ceritinib/Trametinib

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.

Related Keywords

Zeynep Eroglu , Keiran Smalley , Moffitt Cancer Center , Department Of Oncologic Sciences , Cutaneous Oncology , Oncologic Sciences , South Florida Morsani College , Melanoma , Ceritinib And Trametinib , D , Taacr ,